Avicanna (TSX:AVCN) Reports Q3 2025 Financial Results and Corporate Highlights

TORONTO, November 14, 2025 — Leads & Copy — Avicanna Inc., a biopharmaceutical company specializing in plant-derived cannabinoid-based products, has released its Q3 2025 results, showcasing continued progress in its diversified business strategy.

According to Aras Azadian, CEO of Avicanna Inc., the company is pleased with the impact of medical affairs initiatives and strengthened engagement within the Canadian medical community, leading to consecutive quarters of revenue growth in Canada. He also noted that the company continues to translate scientific leadership into tangible value through new IP and global collaborations. While short-term margin pressures exist, Avicanna remains confident in its path toward sustainable profitability.

Key financial highlights from Q3 2025 include:

Revenue: Avicanna generated $6.40 million in revenue for the three-month period and $18.88 million for the nine-month period ending September 30, 2025. Canadian revenue saw a 4% increase, marking the second consecutive quarter of growth, driven by investments in medical affairs initiatives. International revenue also increased by approximately 6% compared to Q2 2025.

Gross Profit and Margin: Gross profit was $3.15 million for the three-month period and $9.88 million for the nine-month period, resulting in gross margins of 49% and 52%, respectively. The short-term reduction in gross margin from 57% in the prior year period is attributed to non-recurring costs, the Canada Post strike, and one-time adjustments. The nine-month margin represents a slight improvement from 50% in the prior period, largely due to sales mix changes from product sales to licensing and service revenue.

Adjusted EBITDA: The company reported an adjusted EBITDA loss of $0.79 million for the three-month period, a decrease from 2024. The nine-month adjusted EBITDA loss was $0.61 million, a slight improvement from the $0.72 million loss in 2024. The reduction in adjusted EBITDA is attributed to the reduction in gross margins.

Other corporate highlights from Q3 2025 include:

Canadian Commercial Advancements: Record sales of 62,987 units, a 39% increase from the same period in 2024. The company had 52 commercial SKUs and 174 commercial listings across medical and adult use channels, representing 29% growth in total listings from Q3 2024, and 18% growth from Q2 2025. The MyMedi.ca platform delivered its second consecutive quarter of growth due to Medical Affairs efforts, while B2B Medical achieved a 113% increase in products sold. The adult-use business expanded into Newfoundland, Yukon, and the Northwest Territories.

Patent Issuance: The United States Patent & Trademark Office issued patent No. US 12,343,315 B2, covering topical cannabinoid compositions for clear skin, including a topical gel formulation comprised of cannabinoids in combination with antioxidants, anti-microbial agents, and anti-inflammatory agents for treating and preventing skin conditions like acne, wrinkles, rosacea, and erythema.

Export of CBD Dominant Cannabis Flower: Avicanna’s subsidiary, SMGH, completed its first export of organic certified flower into Switzerland. This marks the 20th international market for Aureus branded products and the 23rd market for all Avicanna products.

re+PLAY Launch: Avicanna LATAM SAS and Harrington Wellness launched re+PLAY CBD Wellness Brand Topicals in the United States. Re+PLAY is Al Harrington’s CBD wellness brand, utilizing Avicanna’s patented and proprietary CBD formulations. The product line includes a 3% CBD localized cream and a 2% CBD and 1% CBG transdermal gel using Avicanna’s patented deep tissue technology. The CBD and CBG are derived from USDA organic certified hemp cultivated in Avicanna’s subsidiary Santa Marta Golden Hemp SAS and manufactured by Avicanna LATAM SAS’s team in Colombia.

For further information, contact Ivana Maric at info@avicanna.com.

Source: Avicanna Inc.

×

Welcome!

CannabisReporter.news is a Leads & Copy Publication

Leads & Copy is a Media “news tip” source, providing Industry Reporters story Leads, written as Publishable CP-style Copy

By Subscribing you will receive Daily Cannabis Story Leads via email 10:30 am ET Mon-Fri.